Evidence map›Paper›PMID 39031319›Full record

ArticleHepatology international2024

The impact of artificial liver support system on intestinal microbiota and serum bile acid profiles in patients with acute-on-chronic liver failure: a prospective cohort study.

Yuyu Zeng, Dakai Gan, Kaige Zhang, Tao Long, Yan He, Rui Zhou, Shuanglan Liu, Molong Xiong

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Review
  7. [Progress and prospects on liver support therapy for liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuyu Zeng *Infectious Diseases Affiliated Hospital, Jiangxi Medical College, Nanchang University, NO.167, Qingshan Lake Avenue, Nanchang, 330000, China.
Dakai Gan *Infectious Diseases Affiliated Hospital, Jiangxi Medical College, Nanchang University, NO.167, Qingshan Lake Avenue, Nanchang, 330000, China.
Kaige Zhang *The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, NO.17, Minde Road, Nanchang, 330000, China.
Tao LongInfectious Diseases Affiliated Hospital, Jiangxi Medical College, Nanchang University, NO.167, Qingshan Lake Avenue, Nanchang, 330000, China.
Yan HeInfectious Diseases Affiliated Hospital, Jiangxi Medical College, Nanchang University, NO.167, Qingshan Lake Avenue, Nanchang, 330000, China.
Rui ZhouInfectious Diseases Affiliated Hospital, Jiangxi Medical College, Nanchang University, NO.167, Qingshan Lake Avenue, Nanchang, 330000, China.
Shuanglan LiuInfectious Diseases Affiliated Hospital, Jiangxi Medical College, Nanchang University, NO.167, Qingshan Lake Avenue, Nanchang, 330000, China.
Molong XiongInfectious Diseases Affiliated Hospital, Jiangxi Medical College, Nanchang University, NO.167, Qingshan Lake Avenue, Nanchang, 330000, China. xml86005@163.com.ORCID http://orcid.org/0000-0003-4701-6002

Funding

Science and Technology Project of Health Commission of Jiangxi Province 202410568
6 · The paper itself

Abstract

backgroundAcute-on-chronic liver failure (ACLF) patients exhibit an imbalance in intestinal microbiota, and bile acids (BAs) can affect the composition of intestinal microbiota. Although Artificial liver support system (ALSS) is a treatment for ACLF, the impact of ALSS on intestinal microbiota and serum BA profiles of ACLF patients remains unclear.

methodsA prospective study was conducted, which included 51 patients diagnosed with ACLF. These patients were stratified into two groups based on the utilization of an ALSS during their treatment period: a standard medical treatment group (SMT group), comprising 19 patients, and an ALSS combined with SMT group (ALSS group), comprising 32 patients. Blood and stool samples were collected from the patients on the day of admission and 14 days after treatment. Additionally, eight healthy controls were recruited, and their stool samples were also collected. The intestinal microbiota was sequenced using the 16S rRNA sequencing technique, while the serum BA profiles were determined using ultra-performance liquid chromatography/mass spectrometry.

resultsACLF patients exhibited imbalances in intestinal microbiota and abnormalities in BA profiles. Compared to SMT alone, the combined ALSS and SMT was more effective in regulating intestinal microbiota imbalance and increasing the concentrations of ursodeoxycholic acid and glycoursodeoxycholic acid. Correlation analysis revealed a significant correlation between intestinal microbiota and Bas. Furthermore, the preliminary correlation heatmap indicated that the Faecalibaculum, Gemmiger, and taurochenodeoxycholic acid were associated with clinical improvement.

conclusionsOur study identified the compositional characteristics of the intestinal microbiota and serum BA in ACLF patients, emphasizing the impact of ALSS on both intestinal microbiota and serum BA profiles.

Indexed as

Acute-On-Chronic Liver FailureBile Acids and SaltsGastrointestinal MicrobiomeLiver, ArtificialAdultFecesFemaleHumansMaleMiddle AgedProspective StudiesBile Acids and SaltsAcute-on-chronic liver failureArtificial liver support systemBile acidIntestinal microbiota

Identifiers

PMID39031319

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.